Skyward Specialty Insurance Group, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Skyward Specialty Insurance Group, Inc. (SKWD), a Delaware corporation and emerging growth company, on May 7, 2024, covering events occurring on May 6, 2024. The filing details the entry into a material definitive agreement regarding a secondary offering of common stock.
Key Financial Metrics and Transaction Details
This filing does not report operational financial metrics such as revenue, profit, cash flow, or margins. The primary financial data relates to a secondary equity offering:
- Selling Stockholder: Westaim HIIG GP Inc.
- Shares Offered: Up to 5,060,000 shares of common stock.
- Over-Allotment Option: Includes an option for underwriters to purchase up to 660,000 additional shares.
- Offering Price: $36.50 per share.
- Underwriters: Barclays Capital Inc., Keefe, Bruyette & Woods, Inc., and Jefferies LLC.
- Expected Closing Date: May 9, 2024.
Material Changes and Agreements
The Company entered into an Underwriting Agreement on May 6, 2024. Key terms include:
- Lock-Up Period: Executive officers and directors agreed to a 90-day lock-up period restricting sales of the Company's common stock, subject to certain exceptions.
- Indemnification: The Company agreed to indemnify the Underwriters against certain liabilities under the Securities Act.
- Registration: The offering was made pursuant to an effective Form S-3 registration statement (No. 333-279129).
Outlook, Risks, and Management Commentary
The filing indicates the offering is expected to close on May 9, 2024, subject to customary closing conditions. The Company issued press releases on May 6, 2024, announcing both the proposed offering and the pricing of the shares. No specific forward-looking guidance regarding future earnings or operational outlook is provided in this document. The filing notes that the summary is qualified in its entirety by the full text of the Underwriting Agreement.
Key Facts for Investor Verification
- Verify the final closing date of the offering, which is expected to be May 9, 2024.
- Confirm whether the underwriters exercised the 30-day option to purchase the additional 660,000 shares.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification clauses and representations.
- Monitor the impact of the 90-day lock-up period on executive and director share liquidity.
- Note that proceeds from this secondary offering go to the Selling Stockholder (Westaim HIIG GP Inc.), not the Company.